Back to top

crispr: Archive

Sundeep Ganoria

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?

The decline in CRSP's share price could be due to the beating the drug/biotech sector has been taking in the past couple of months, resulting from pipeline setbacks and guidance cuts.

VRTXPositive Net Change BEAMPositive Net Change EDITPositive Net Change CRSPPositive Net Change

Zacks Equity Research

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

BIIBPositive Net Change VRTXPositive Net Change FOLDPositive Net Change CRSPPositive Net Change

Zacks Equity Research

CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?

On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.

REGNPositive Net Change PFEPositive Net Change VRTXPositive Net Change CRSPPositive Net Change

Ekta Bagri

5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.

EXELPositive Net Change FOLDPositive Net Change BPMCPositive Net Change CRSPPositive Net Change VRNANegative Net Change